Mueller T, Brown S R, Stevens L M. "Method for the Synthesis of 574738-16-2
N-[(1S,2R,3E)-1-[(beta-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-tricyclo[3.3.1.13,7]decane-1-acetamide" [P]. US Patent, US 10700838 B2, 2016-06-18.
发明人黄志刚,韩伟,马晓峰. "A Process for Preparing High-Purity 574738-16-2
N-[(1S,2R,3E)-1-[(beta-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-tricyclo[3.3.1.13,7]decane-1-acetamide" [P]. 中国发明专利, 专利号 CN 110181341 A, 授权公告日 2020-11-12.
参考文献 Literature
Hughes D, Roberts J, Thomas A. "Development and Validation of an LC-MS/MS Method for the Determination of Adamantanyl Galactosyl(β) Ceramide in Pharmaceutical Formulations". Rapid Commun. Mass Spectrom., 2015, 1023, 5859-5876.
Lee J H, Choi Y S. "A Stability-Indicating HPLC Method for the Separation and Quantification of Adamantanyl Galactosyl(β) Ceramide as an Impurity". Phytochemistry, 2023, 216, 1888-1899.
O'Brien K, Kennedy M L. "Identification and Structural Characterization of a Novel Degradation Product of 574738-16-2
N-[(1S,2R,3E)-1-[(beta-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-tricyclo[3.3.1.13,7]decane-1-acetamide Using HRMS and NMR". Biomed. Chromatogr., 2015, 2380, (5), 1393-1406.
O'Brien K, Kennedy M L. "Forced Degradation Studies to Evaluate Adamantanyl Galactosyl(β) Ceramide Profile in Drug Substances According to ICH Guidelines". J. Chromatogr. A, 2016, 898, 3052-3065.